Current Reports (8-K / 6-K)

EMERALD-3 Phase III trial met its primary endpoint of progression-free survival (PFS) with statistical significance in embolisation-eligible unresectable hepatocellular carcinoma (HCC).

The combination of Imfinzi, Imjudo, lenvatinib, and TACE showed a trend toward improved overall survival (OS) versus TACE alone at interim analysis.

The STRIDE regimen plus TACE arm also showed strong trends toward improved PFS and OS, although not formally tested at this time.

Safety profiles for the combinations were consistent with the known profiles of the medicines, with no new safety findings identified.

AstraZeneca is discussing the positive data with global regulatory authorities while awaiting final results for key secondary endpoints.

EMERALD-3 Phase III trial met its primary endpoint of progression-free survival (PFS) with statistical significance in embolisation-eligible unresectable hepatocellular carcinoma (HCC).

The combination of Imfinzi, Imjudo, lenvatinib, and TACE showed a trend toward improved overall survival (OS) versus TACE alone at interim analysis.

The STRIDE regimen plus TACE arm also showed strong trends toward improved PFS and OS, although not formally tested at this time.

Safety profiles for the combinations were consistent with the known profiles of the medicines, with no new safety findings identified.

AstraZeneca is discussing the positive data with global regulatory authorities while awaiting final results for key secondary endpoints.

Signed $60.0 million revolving credit facility with a leading European Financial Institution.

Facility tenor of five years with interest at Term SOFR plus margin.

Secured by first priority mortgage over four Company vessels.

Net proceeds for general corporate purposes.

Company operates two LPG carriers and one MR tanker.

Michael K. Kneller, Vice President, General Counsel and Secretary since 2005, resigns May 8, 2026 to join Scopelitis, Garvin, Light, Hanson & Feary, P.C.

Vallie S. Dugas, current Vice President and Assistant General Counsel, named Interim Vice President, General Counsel and Secretary effective May 8, 2026.

Departure announced April 2, 2026.

Kneller's exit removes long-tenured legal leadership.

Interim appointment ensures continuity in key legal oversight role.

Blue Bird acquired the remaining 50% interest in Micro Bird, becoming the sole owner of the joint venture enterprise.

The aggregate purchase price was $201,787,193, paid roughly 30% in cash ($63.0 million) and 70% in stock ($138.8 million).

The stock consideration involves 2,702,180 shares, issued as exchangeable shares subject to a six-month lock-up with staggered release through 2029.

Steve Girardin was appointed as a Class III Director effective March 30, 2026, with a term expiring at the 2029 annual stockholder meeting.

A Special Voting Preferred Stock was created to provide voting rights to holders of the Exchangeable Shares equivalent to common stockholders.

The acquisition strengthens Blue Bird's portfolio with Buy America-compliant shuttle buses and Type A school buses.

John Achille promoted to President and COO effective immediately on April 1, 2026.

Achille retains oversight of Installation Services and Specialty Distribution day-to-day operations.

New responsibilities include Supply Chain organization and all growth initiatives such as M&A.

Achille continues reporting to CEO Robert Buck.

Promotion signals internal leadership continuity and focus on profitable growth.

Achille joined TopBuild in 2021 via acquisition and has held progressive leadership roles.

F-Series sold 159,901 trucks — America’s No. 1 truck for Q1 — with March volume at 62,238, the quarter’s highest; reflects continued demand despite tight dealer supply.

Large SUV sales (Bronco, Explorer, Expedition) rose 17.9% — best Q1 start since 2002 — lifting retail share amid Escape and Corsair sunsetting.

Explorer sales surged 29.7% to 61,387 units, extending its lead as America’s top three-row SUV; Expedition up 30.2% to 17,554 units.

Ford Pro paid software subscriptions grew ~29% to >865,000, and BlueCruise surpassed 10.1 million cumulative hands-free driving hours.

Commercial vehicle leadership continued: Ford ranked No. 1 in U.S. Class 1–7 trucks/vans in January, with share up 1 percentage point YoY.

Lincoln Aviator sales jumped 31.4% to 6,266 units — record Q1 — while Navigator rose 6.5% to 4,322 units.

F-Series sold 159,901 trucks — America’s No. 1 truck for Q1 — with March volume at 62,238, the quarter’s highest; reflects continued demand despite tight dealer supply.

Large SUV sales (Bronco, Explorer, Expedition) rose 17.9% — best Q1 start since 2002 — lifting retail share amid Escape and Corsair sunsetting.

Explorer sales surged 29.7% to 61,387 units, extending its lead as America’s top three-row SUV; Expedition up 30.2% to 17,554 units.

Ford Pro paid software subscriptions grew ~29% to >865,000, and BlueCruise surpassed 10.1 million cumulative hands-free driving hours.

Commercial vehicle leadership continued: Ford ranked No. 1 in U.S. Class 1–7 trucks/vans in January, with share up 1 percentage point YoY.

Lincoln Aviator sales jumped 31.4% to 6,266 units — record Q1 — while Navigator rose 6.5% to 4,322 units.

F-Series sold 159,901 trucks — America’s No. 1 truck for Q1 — with March volume at 62,238, the quarter’s highest; reflects continued demand despite tight dealer supply.

Large SUV sales (Bronco, Explorer, Expedition) rose 17.9% — best Q1 start since 2002 — lifting retail share amid Escape and Corsair sunsetting.

Explorer sales surged 29.7% to 61,387 units, extending its lead as America’s top three-row SUV; Expedition up 30.2% to 17,554 units.

Ford Pro paid software subscriptions grew ~29% to >865,000, and BlueCruise surpassed 10.1 million cumulative hands-free driving hours.

Commercial vehicle leadership continued: Ford ranked No. 1 in U.S. Class 1–7 trucks/vans in January, with share up 1 percentage point YoY.

Lincoln Aviator sales jumped 31.4% to 6,266 units — record Q1 — while Navigator rose 6.5% to 4,322 units.

F-Series sold 159,901 trucks — America’s No. 1 truck for Q1 — with March volume at 62,238, the quarter’s highest; reflects continued demand despite tight dealer supply.

Large SUV sales (Bronco, Explorer, Expedition) rose 17.9% — best Q1 start since 2002 — lifting retail share amid Escape and Corsair sunsetting.

Explorer sales surged 29.7% to 61,387 units, extending its lead as America’s top three-row SUV; Expedition up 30.2% to 17,554 units.

Ford Pro paid software subscriptions grew ~29% to >865,000, and BlueCruise surpassed 10.1 million cumulative hands-free driving hours.

Commercial vehicle leadership continued: Ford ranked No. 1 in U.S. Class 1–7 trucks/vans in January, with share up 1 percentage point YoY.

Lincoln Aviator sales jumped 31.4% to 6,266 units — record Q1 — while Navigator rose 6.5% to 4,322 units.

Nasdaq issued a Staff Delisting Determination Letter on March 27, 2026, citing the low bid price rule.

The closing bid price remained at $0.10 or below for 10 consecutive trading days through March 25, 2026.

Trading in the Company's ADSs will be suspended at the opening of business on April 6, 2026.

The Company intends to appeal the delisting determination to the Nasdaq Hearings Panel.

A hearing request will not stay the trading suspension scheduled for April 6, 2026.

Oncotelic and TechForce executed a binding Joint Development, Manufacturing, and Licensing Agreement effective March 31, 2026 — establishes formal collaboration framework with defined IP ownership and development obligations.

The integrated Product combines TechForce’s robotic hardware with Oncotelic’s proprietary PDAOAI Platform — creates a novel AI-robotics solution targeted specifically at GMP-regulated pharmaceutical manufacturing.

All AI-related foreground IP, including PDAOAI improvements, is owned exclusively by Oncotelic — strengthens Oncotelic’s control over core AI assets and future commercialization rights.

Data generated through Product operation, deployment, and testing is owned exclusively by Oncotelic — enhances data sovereignty and supports regulatory submissions and product validation.

Commercial terms (revenue sharing, royalties, profit-sharing) are deferred to a future Commercialization and Licensing Agreement — no revenue-generating activities may commence without mutual written consent.

TechForce is restricted for 12 months post-termination from licensing jointly developed IP to third parties in pharmaceutical/biopharmaceutical manufacturing — provides Oncotelic with competitive protection during transition.

Nasdaq determined the Company complies with continued listing standards, closing the matter.

Compliance follows the filing of the Annual Report on Form 10-K on March 31, 2026.

The Form 10-K evidenced stockholders' equity of $3,953,682.

The Company had previously received a non-compliance notice from Nasdaq on December 1, 2025.

The Group assessed the FCA's final motor finance redress rules and concluded no current adjustment to its provision is required.

Uncertainties persist around customer response rates, operational implementation costs, and potential legal proceedings.

The ultimate financial impact may differ depending on actions by customers, regulators, or courts, including complaints and litigation.

An update on the matter will be provided with the Group's first quarter results at the end of April 2026.

The Group assessed the FCA's final motor finance redress rules and concluded no current adjustment to its provision is required.

Uncertainties persist around customer response rates, operational implementation costs, and potential legal proceedings.

The ultimate financial impact may differ depending on actions by customers, regulators, or courts, including complaints and litigation.

An update on the matter will be provided with the Group's first quarter results at the end of April 2026.

The Group assessed the FCA's final motor finance redress rules and concluded no current adjustment to its provision is required.

Uncertainties persist around customer response rates, operational implementation costs, and potential legal proceedings.

The ultimate financial impact may differ depending on actions by customers, regulators, or courts, including complaints and litigation.

An update on the matter will be provided with the Group's first quarter results at the end of April 2026.

Drs. Frances Arnold, Robert S. Epstein, and Gary S. Guthart to retire as directors effective May 21, 2026.

Retirements not due to any dispute or disagreement with the Company or Board.

Board nominates David P. King for election at 2026 annual meeting of stockholders.

David P. King is former Executive Chairman and CEO of Laboratory Corporation of America Holdings.

King currently serves as director and chair of Privia Health and AmSurg Corporation, and director of Smith & Nephew.

Produced 408,386 vehicles in Q1 2026, including 394,611 Model 3/Y and 13,775 other models.

Delivered 358,023 vehicles in Q1 2026, with 341,893 Model 3/Y and 16,130 other models.

Deployed 8.8 GWh of energy storage products in Q1 2026.

Financial results to be released April 22, 2026 after market close.

Q&A webcast scheduled for April 22, 2026 at 4:30 p.m. CT on ir.tesla.com.

Deliveries and deployments not indicators of quarterly financial results.

Shareholders approved re-designating 20,000,000 shares as Class A Ordinary Shares, resulting in 518,911,230 Class A Ordinary Shares and 81,088,770 Class B Ordinary Shares.

The company's memorandum and articles of association were amended and restated to incorporate the approved resolutions.

The 2026 Share Scheme was adopted, including approval of grants of 1,400,000 RSUs to Dr. Jun Peng and 600,000 RSUs to Dr. Tiancheng Lou.

Directors were granted a general mandate to issue, allot, and deal with additional Class A ordinary shares and/or ADSs not exceeding 20% of total issued shares.

Directors were granted a general mandate to repurchase shares and/or ADSs not exceeding 10% of total issued shares.

Giannis Antetokounmpo joined as a Global Partner and shareholder of IM8, receiving equity instead of cash compensation, signaling strong alignment with Prenetics' long-term vision.

IM8 reached $100M annualized recurring revenue within 11 months of launch (December 2024), a record pace for the supplement industry.

IM8 is projected to generate $180M–$200M in full-year 2026 revenue and has delivered over 22 million servings to 750,000+ customers across 31 countries.

Prenetics reported approximately $160M in adjusted liquidity as of March 1, 2026, with zero debt and adjusted EBITDA profitability targeted by Q4 2027.

The partnership expands IM8’s reach to Giannis’s 35M+ social followers and leverages NBA broadcast coverage in 215 countries to accelerate international market activation.

Giannis Antetokounmpo joined as a Global Partner and shareholder of IM8, receiving equity instead of cash compensation, signaling strong alignment with Prenetics' long-term vision.

IM8 reached $100M annualized recurring revenue within 11 months of launch (December 2024), a record pace for the supplement industry.

IM8 is projected to generate $180M–$200M in full-year 2026 revenue and has delivered over 22 million servings to 750,000+ customers across 31 countries.

Prenetics reported approximately $160M in adjusted liquidity as of March 1, 2026, with zero debt and adjusted EBITDA profitability targeted by Q4 2027.

The partnership expands IM8’s reach to Giannis’s 35M+ social followers and leverages NBA broadcast coverage in 215 countries to accelerate international market activation.

Company received Nasdaq non-compliance notice on December 31, 2025, for bid price below $1.00 for 30 consecutive business days.

Implemented reverse stock split effective March 6, 2026, trading on split-adjusted basis from March 9, 2026.

Hearings Panel granted exception period until March 20, 2026, to achieve $1.00 bid price for 10 consecutive business days.

Common stock closed at $7.47 on March 20, 2026, meeting compliance requirement.

Nasdaq confirmed full compliance with all listing requirements on March 31, 2026.

Subject to Mandatory Panel Monitor until March 31, 2027, with potential delisting hearing if non-compliant.

The company has over $37 billion in assets under management as of December 31, 2025, diversified across all major commercial real estate sectors.

Approximately 70% of services revenues are derived from 20-year evergreen contracts with significant termination provisions, providing durable earnings.

The company's Adjusted EBITDA margin has been over 40% annually, reflecting a highly profitable business model.

RMR increased its quarterly dividend to $0.45 per share in April 2024 and has a track record of dividend growth.

The company has nearly $150 million of total liquidity and is positioned for growth with a scalable infrastructure.

RMR trades at a valuation discount to industry peers, presenting a meaningful upside opportunity according to the presentation.

The Company is authorized to issue 10 billion shares divided into Class A, B, and C ordinary shares with distinct voting rights.

Class A shares carry 1 vote per share, while Class B and Class C shares carry 50 and 500 votes per share respectively.

Class B and Class C shares are convertible into Class A ordinary shares at the option of the holder on a 1:1 basis.

The amendment was adopted by Directors' resolutions on March 4, 2026 and filed with the Registrar on April 1, 2026.

Class A shares are not convertible into Class B or Class C shares at any time.

Divested 100% equity of Particle, Inc. for $1 cash plus 10% revenue share on covered products for up to 5 years.

Buyer assumes all business obligations including Seattle office lease.

Issued secured promissory note up to $450,000 at 10% interest maturing September 23, 2026.

Ronald P. Erickson departed as Board member and Science Division President effective March 27, 2026.

Transaction approved by independent Audit Committee; not material to financial statements.

Strategic shift to focus on core fintech tokenized deposit offering.

The company acquired assets and licenses for Honeywell's general aviation autopilot, nav/com, display, and transponder product lines for $22.0 million in cash.

The company acquired assets and licenses for Honeywell's electronic generator and generator control unit for the F-15 and 767 platforms for $8.0 million in cash.

Both transactions closed concurrently with the signing of the agreements, representing completed acquisitions.

The agreements include customary representations, warranties, covenants, and mutual indemnification obligations.

Transition Services Agreements were also executed, under which Honeywell will provide technical support to assist the company in manufacturing, repairing, and servicing the licensed products.

Submitted CardiAMP HF clinical study data to the FDA — first formal regulatory submission for the CardiAMP® System in ischemic HFrEF.

Requested FDA meeting this quarter under Breakthrough Therapy designation — timing aligns with prior regulatory guidance and signals advancement toward potential accelerated approval.

Meeting objectives include FDA feedback on acceptability of approval based on safety, clinical response in 125 ischemic HFrEF patients, and benefit in elevated biomarker subgroup.

In the elevated biomarker subgroup, CardiAMP showed 47% relative risk reduction in all-cause cardiac death and 37% reduction in non-fatal major adverse cardiac events versus guideline-directed medical therapy alone.

Results presented at THT 2026 Annual Meeting and posted on BioCardia’s website — public validation of clinical data by a peer-reviewed forum.

Company exchanged Prior Notes for Exchange Note with original principal of $2,681,718.42 including OID of $242,883.49 and $10,000 transaction expenses.

Interest rate reduced from 18% per annum on Prior Notes to 6% per annum compounded daily on Exchange Note.

Maturity extended from March 31, 2026 to July 1, 2027.

Streeterville can require monthly redemptions up to $111,738.27 starting July 1, 2026.

Obligations guaranteed by subsidiary Virtuix Inc.

Exchange qualifies under Section 3(a)(9) of Securities Act with tacked holding period from Prior Notes' issuance dates.

Dr. Howard Berman resigned as Executive Chairman and Director effective April 1, 2026, following a planned CEO transition process initiated in November 2024.

Mark H. Pavao was appointed as an independent Class III Director to fill the vacancy, with a term expiring at the 2028 annual meeting.

The Company entered into a Separation Agreement with Dr. Berman providing for a prorated 2026 bonus and 12 months of continued stock option vesting.

Mr. Pavao brings over 30 years of biopharmaceutical leadership experience and will receive an option to purchase 10,000 shares of common stock.

Parties: Itaú Unibanco Holding S.A. and Itaú Unibanco S.A. with Porto Seguro S.A., Porto Seguro Seguros Del Uruguay S/A, and Azul Companhia de Seguros Gerais.

Transaction: Operating Agreement for promotion and sale of Porto Seguro insurance via Itaú Unibanco channels.

Remuneration exceeded BRL 50 million monthly per CVM Resolution 80/22 threshold.

Management confirms compliance with commutative conditions and related party policy.

Recurring in normal course of business; no further disclosures for 2026.

Estimated total 2026 remuneration: approximately BRL 441 million.

Agreement dated April 1, 2026, between Company and Purchaser(s) listed in Exhibit A.

Issuing up to 20,000 Class B ordinary shares, par value $0.000012 each.

Purchase price of $3.20 per share.

Purchaser is a non-US person under Regulation S, for own account.

Closing at offices of Hunter Taubman Fischer & Li LLC upon conditions met.

Pre-agreement capitalization: 944,784 Class A and 3,846 Class B ordinary shares outstanding.

FDA accepted for review the resubmitted Biologics License Application for UX111 gene therapy for Sanfilippo syndrome Type A.

The FDA set a Prescription Drug User Fee Act action date of September 19, 2026.

The company is seeking accelerated approval for UX111.

The press release contains forward-looking statements about the development, regulatory review, and potential approval of UX111.

Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially.

Holders of the company's units can elect to separate them into Class A ordinary shares and warrants starting April 6, 2026.

Separated Class A ordinary shares will trade under the symbol 'WLII' and warrants under 'WLIIW' on the Nasdaq Global Market.

Units that are not separated will continue to trade under the symbol 'WLIIU' on the Nasdaq Global Market.

Each whole warrant entitles the holder to purchase one Class A ordinary share for $11.50.

Holders must have their brokers contact Continental Stock Transfer & Trust Company to separate units into shares and warrants.

Selig Zises resigned effective March 31, 2026, citing personal health and related disability.

The resignation was not due to any disagreement with the Company, the Bank, or their affiliates.

Mr. Zises served for more than 17 years on the Board.

The Board of Directors was reduced from nine to eight directors following the resignation.

Entered master services agreement with Iterative Health (d/b/a Iterative Health) on March 30, 2026, to assist with patient enrollment for the expected Phase 2 study of PALI-2108 in moderate-to-severe UC — accelerates clinical execution readiness.

Issued and sold 1,536,885 shares of common stock to an affiliate of Iterative Health on March 27, 2026, for $3.0 million total consideration — provides non-dilutive capital aligned with clinical development partner.

Pricing of $1.952 per share was set at the five-day Nasdaq Capital Market average closing price prior to March 27, 2026 — establishes objective, market-based valuation for the private placement.

Offering exempt from registration under Section 4(a)(2) of the Securities Act — confirms reliance on private placement exemption without public registration or prospectus.

Received signed purchase order from Latin American public safety organization for drone-based operational systems and integrated payloads.

Order includes long-range quadrotor platforms, EO/IR imaging, network connectivity, and specialized aerial payloads for defense and surveillance missions.

Phased deployment structure with initial tranche in 2026, subject to delivery milestones, quantity confirmations, and standard commercial terms.

Follows technical presentations to government officials referenced in March 16, 2026 press release.

No assurance of full completion or revenue realization due to customary conditions including performance and acceptance.

Potential foundation for broader engagements in the jurisdiction and region if initial deployment succeeds.

All seven directors re-elected with majority support, Samarth Verma receiving lowest For votes at 2,543,827.

Merger with New Asia Holdings Inc. and Preferred Stock conversion failed with 3,839,210 For vs 306,347 Against.

RBSM LLP ratified as independent auditor for 2025 with 5,293,058 For votes.

Nasdaq-compliant share issuances to Generating Alpha Ltd. and JAK Industrial Ventures I LLC approved.

Authorized Common Stock increased from 75M to 3B shares; reverse stock split (1:10-1:20) approved.

Stock Incentive Plan expanded by 1.5M shares plus annual 4.5% evergreen increase approved.

Acquired all membership interests of RPD Technologies Americas from controlling shareholder Abundia Financial for $4.04 million, payable via a convertible note.

Issued a $4.04 million senior secured convertible note to Abundia Financial with 10% annual interest, maturing on the first anniversary of closing.

The convertible note can be converted into common stock after maturity at 80% of the average VWAP over three trading days, subject to a $0.29 per share floor price.

Granted a security interest in the acquired membership interests to Abundia Financial as collateral for the convertible note obligation.

The acquisition adds an immediate revenue stream and expands Abundia's vertically integrated waste-to-value business model with RPD's project development capabilities.

The securities issued were not registered under the Securities Act, relying on exemptions for transactions not involving a public offering.

FDA granted Fast Track designation to CDI-988, the first oral antiviral for norovirus treatment and prophylaxis.

Designation enables frequent FDA communication, rolling NDA review, and potential Priority Review.

Phase 1b challenge study underway at Emory University evaluating CDI-988 in up to 40 healthy adults.

CDI-988 targets conserved region of norovirus, coronavirus, and other 3CL proteases.

Norovirus causes 685 million global cases yearly with $60 billion economic impact.

Tender offer expired April 1, 2026, with $110,390,000 Notes tendered after Early Tender Date.

Total Notes accepted for purchase: $893,995,000, below $1,000,000,000 maximum.

Includes $783,605,000 previously accepted on March 19, 2026.

Settlement for late tenders on April 3, 2026.

Notes originally issued by Civitas, assumed by SM Energy post-merger.

No minimum tender condition; offer managed by BofA Securities and D.F. King.

Annual Meeting scheduled for May 6, 2026 at 12:00 p.m. Toronto time, conducted virtually via live audio webcast — enables broader shareholder participation but restricts physical attendance.

Meeting agenda includes receipt of audited consolidated financial statements for fiscal year ended December 31, 2025 — no financial results or performance commentary disclosed in this filing.

Directors to be elected for the ensuing year; nominees explicitly named: Ronald Dewhurst, Graham Birch, Barbara Connolly Keady, Dinaz Dadyburjor, Whitney George, Judith W. O’Connell, and Catherine Raw — no changes to board composition disclosed.

KPMG LLP to be re-appointed as auditor with Board authorized to fix remuneration — no auditor change or qualification disclosed.

Notice-and-access delivery used per NI 51-102 and NI 54-101 — reduces paper use and mailing costs; meeting materials posted online at sedarplus.ca and sprott.com/investor-relations/2026-agm.

Record date is March 17, 2026; proxy deadline is May 4, 2026 at 12:00 p.m. Toronto time — late proxies subject to Chair’s discretion.

Seth Kalvert will leave his position as Chief Legal Officer and Secretary effective May 1, 2026.

The departure is treated as a Qualifying Termination under the Amended and Restated Executive Severance Plan.

Mr. Kalvert's departure involves no disagreement with the Company regarding operations, policies, or practices.

Mr. Kalvert has agreed to remain available in an advisory capacity to assist with transition services.

US District Court for the Southern District of New York largely denied defendants' joint motion to dismiss the lawsuit.

Lawsuit alleges spoofing techniques manipulated Quantum BioPharma share price between January 1, 2020, and August 15, 2024.

Claims violate Section 10(b), Rule 10b-5(a) and (c), and Section 9(a) of the Securities Exchange Act of 1934.

Court's full ruling available as District Court Opinion & Order.

Claim referenced as USD $700,000,000 in exhibit title.

Q1 2026 production totaled 10,236 vehicles at the Normal, Illinois manufacturing facility.

Q1 2026 deliveries totaled 10,365 vehicles, exceeding production for the quarter.

Management stated quarterly results are in line with the company's outlook.

The company reaffirmed 2026 annual delivery guidance in the range of 62,000 to 67,000 vehicles.

Q1 2026 financial results are scheduled for release on April 30, 2026, after market close.

Entered Merger Agreement on April 2, 2026, to acquire The Container Store Holdings, LLC through Merger Sub merger.

Merger consideration: $150M Purchase Price via Buyer Common Stock at $7.00/share and senior convertible notes with $54M minimum, subject to 19.99% ownership cap.

Buyer Convertible Notes: 5% interest, 7-year maturity, initial conversion at ~$9.10/share, interest escalates without stockholder approval.

Appointed Brian LaRose as CFO effective April 28, 2026, succeeding Adrianne B. Lee; Amy E. Sullivan as President and Lisa Foley as COO tied to TBHC merger.

Support Agreement signed by holders of 80.47% TCS equity and 90.75% term loans.

Closing subject to lender approvals, $55M new loans, financial statements, no later than September 30, 2026.

Off The Hook YS Inc. entered a definitive agreement to acquire Bellhart Marine Group and its affiliated entities.

The acquisition aims to build a premier marine 'Mega Service & Refit Center' platform in the Carolinas.

The transaction includes three strategic facilities: Cape Fear River Shipyard, Market Street Facility, and Sloop Point Marina.

The acquisition is expected to accelerate inventory reconditioning timelines and improve gross margins.

The transaction is subject to customary closing conditions including due diligence and third-party approvals.

Company added cancer cachexia—a serious, untreatable cancer-associated wasting syndrome affecting up to 80% of advanced cancer patients—as a new core indication.

No FDA-approved therapies currently exist for cancer cachexia in the U.S., representing a major unmet medical need and commercial opportunity.

Global cancer cachexia market projected to grow from $2.54 billion in 2024 to $3.90 billion by 2033, per Grand View Research cited in the filing.

Lead candidate Phyto-N remains in preclinical studies for ulcerative colitis, with a planned IND submission; cancer cachexia expansion is concurrent and complementary.

Strategic pivot aligns with Curanex’s broader focus on serious diseases involving inflammation, metabolic dysfunction, and physical decline.

Q1 2026 tender requests reached 21.9% of shares outstanding as of Dec 31, 2025, with 5% ($988M) fulfilled pro rata, driven by small minority of investors.

Gross inflows of $872M resulted in net outflows of $116M, less than 1% of Dec 31, 2025 NAV.

Liquidity of $11.3B as of Feb 28, 2026 provides 11x coverage of tender; net leverage 0.80x below 0.90x-1.25x target.

Portfolio at $36B fair value as of Dec 31, 2025: 370 companies, 93% senior secured, 91% PE-backed, 0.3% non-accruals.

OCIC Class I annualized return 9.2% since inception through Feb 28, 2026, outperforming public credit indices.

Moody’s upgraded rating from Baa3 to Baa2 in Jan 2026 citing underwriting and track record.

OTIC received estimated tender requests of 40.7% of shares outstanding but will fulfill only 5% on a pro rata basis.

The 5% tender fulfillment totals $179 million, partially offset by $127 million in gross capital inflows.

Liquidity stands at over $1.3 billion as of February 28, 2026, providing approximately 7x coverage of the tender offer.

Net leverage was 0.82x debt-to-equity, below the target range of 0.90x to 1.25x.

Non-accruals remained low at 0.2% of portfolio fair value with a 0.0% average annual net loss rate since inception.

Acquired SE&M entities for $158 million in cash, subject to closing adjustments; potential earnout up to 8% of purchase price based on post-acquisition performance targets.

SE&M generated $109 million revenue and high-teens EBITDA margin in 2025, with ~65% of revenue from mechanical services and ~60% from pharmaceutical and health care end markets.

Transaction enhances Everus’ Southeast presence, diversifies revenue mix, and adds recurring maintenance and retrofit revenue with high client renewal rates.

SE&M leadership—including CEOs Zack and Alex Bynum and President Patrick Rogers—will remain post-acquisition, ensuring continuity and operational execution.

Pro forma net leverage is expected to be 0.8x, preserving financial flexibility for organic growth and additional strategic acquisitions.